"Graft vs Tumor Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
| Descriptor ID |
D020350
|
| MeSH Number(s) |
G12.875.402.320
|
| Concept/Terms |
Graft vs Tumor Effect- Graft vs Tumor Effect
- Graft vs Neoplasm Effect
- Graft-vs-Tumor Response
- Graft vs Tumor Response
- Graft-vs-Tumor Responses
- Response, Graft-vs-Tumor
- Responses, Graft-vs-Tumor
- Graft-vs-Neoplasm Response
- Graft vs Neoplasm Response
- Graft-vs-Neoplasm Responses
- Response, Graft-vs-Neoplasm
- Responses, Graft-vs-Neoplasm
- Graft-vs-Neoplasm Effect
- Effect, Graft-vs-Neoplasm
- Effects, Graft-vs-Neoplasm
- Graft-vs-Neoplasm Effects
- Graft-vs-Tumor Effect
- Effect, Graft-vs-Tumor
- Effects, Graft-vs-Tumor
- Graft-vs-Tumor Effects
|
Below are MeSH descriptors whose meaning is more general than "Graft vs Tumor Effect".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Tumor Effect".
This graph shows the total number of publications written about "Graft vs Tumor Effect" by people in this website by year, and whether "Graft vs Tumor Effect" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 0 | 4 | 4 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Graft vs Tumor Effect" by people in Profiles.
-
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res. 2015 Oct 01; 21(19):4312-20.
-
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13.
-
Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol. 2011 Nov; 23(6):681-91.
-
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6878-87.
-
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
-
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28.
-
Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S138-45.
-
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol. 2008 Nov; 19(11):1935-40.
-
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 2008 Mar; 41(6):505-13.
-
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med. 2006 Sep; 12(9):1039-47.